


Amendments to the Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1. (Currently Amended) A compound of formula I,



(I)

wherein

~~R₁ and R₂ are independently hydrogen, halo, or lower alkyl, heterocycle, amino or cycloalkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-amino-lower alkyl, heterocycle-lower alkyl; or R₁ and R₂ can join together to form a N-heterocycle or lower alkyl-N-heterocycle all of which may be unsubstituted or substituted;~~

~~or R₁ and R₂ can join together to form an unsubstituted or substituted N heterocycle;~~

Y is (R₃)_n-X- or A(R₃)(R₃)C-

wherein

~~X is lower alkylene, amino, amide or carbonyl;~~

~~A is hydroxy, amino, halo, or lower alkyl;~~

~~R₃ is lower alkyl, lower alkoxy, carbonyl, amino, hydroxy, heterocycle-heterocyclic, or heteroaryl, lower alkyl-heterocycle, heterocycle-lower alkyl, lower alkyl-amino-lower alkyl, heterocycle-lower alkyl-amino, lower alkyl-amino, hydroxy-lower alkyl-amino, amino substituted by lower alkoxy-lower alkyl and lower alkyl; all of which can be unsubstituted or substituted;~~

~~n is 1 or 2;~~

~~the substituents on R₃ are one or more substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, amino, hydroxy and heterocycle; all of which, except halo, are unsubstituted or substituted by one or more substituents independently selected from the group consisting of halo, hydroxy, lower alkoxy, amino, lower alkyl and heterocycle; all of which, except halo, are unsubstituted or substituted by one or more substituents independently selected~~

~~from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy and lower alkoxy;~~
~~the substituents on R₁ and R₂ are one or more substituents independently selected from the group~~
~~consisting of halo, hydroxy, lower alkyl, lower alkoxy, amino, cycloalkyl, heterocycle and heteroaryl;~~
~~all of which, except halo, are unsubstituted or substituted by one or more substituents~~
~~independently selected from the group consisting of halo, hydroxy, lower alkyl, lower alkoxy, amino,~~
~~heterocycle and heteroaryl; all of which, except halo, are unsubstituted or substituted by one or~~
~~more substituents independently selected from the group consisting of halo, hydroxy, loweralkyl and~~
~~amino;~~

wherein heterocyclic is selected from pyrrolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl,
piperidinyl, pyranyl, pyrazolidinyl, oxiranyl, dioxanyl, imidazoliny, imidazolidinyl, morpholinoyl and
piperazinyl;

cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and
cyclooctyl;

N-heterocyclic is selected from pyrrolidinyl, imidazoliny, imidazolidinyl, piperidinyl, morpholinoyl,
and piperazinyl;

heteroaryl is selected from pyridyl, ~~indoyl~~, indolyl, quinoxaliny, quinoliny, isoquinoliny,
benzothiényl, benzofuranyl, benzopyranyl, benzothiopyranyl, furanyl, pyrrolyl, thiazolyl, oxazolyl,
isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl and thienyl;

or a pharmaceutically acceptable salt, ~~ester~~ thereof.

2.-3. (Cancelled)

4. (Currently Amended) A compound of formula I according to claim 1

R₁ and R₂ are independently hydrogen, methyl, ethyl, propyl, cyclopropyl, hydroxy-propyl,
 dimethylamino-ethyl, morpholinyl-propyl, methoxy-ethyl, pyrrolidinyl-propyl;

or R₁ and R₂ can join together to form a piperazinyl or methyl-piperazinyl, ~~preferably N-methyl-~~
~~piperazinyl;~~

Y is (R₃)_n-X- or A(R₃)(R₃)C-;

wherein

X is CH₂ or -C(O)-;

A is hydroxy;

n is 1;

R₃ is methylene, ethylene, butoxy, morpholinyl, piperazinyl, pyrrolyl, tetrazoyl, imidazolyl, methyl-
 piperazinyl, diethyl-amino-propyl, morpholino-propyl-amino, methyl-amino, hydroxy-propyl-amino,

(methoxy-ethyl)methyl-amino;

or a pharmaceutically acceptable salt or ester thereof.

5. (Currently Amended) A compound of formula I according to claim 1 selected from the group consisting of

methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-propylamine;

[4-(4-methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-morpholin-4-yl-methanone;

[4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-(4-methyl-piperazin-1-yl)-methanone;

dimethyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;

N-(3-diethylamino-propyl)-4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzamide;

[4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-morpholin-4-yl-methanone;

4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-N-(3-morpholin-4-yl-propyl)-benzamide;

(4-methyl-piperazin-1-yl)-{4-[4-(4-methyl-piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-methanone;

4-(4-methyl-piperazin-1-yl)-6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidine;

{4-[4-(ethyl-methyl-amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone;

[4-(4-isopropylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-(4-methyl-piperazin-1-yl)-methanone;

[4-(4-methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-(4-methyl-piperazin-1-yl)-methanone;

isopropyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;

ethyl-methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;

{4-[4-(3-hydroxy-propylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone;

methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;

(4-Methyl-piperazin-1-yl)-[4-(4-propylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-methanone;

{6-[4-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-propyl-amine;

methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-propyl-amine;

[4-(4-Cyclopropylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-(4-methyl-piperazin-1-yl)-methanone;

N-methyl-4-(4-methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzamide;

{4-[4-(2-Dimethylamino-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone;

N,N-dimethyl-N'-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-ethane-1,2-diamine;

[6-(4-Imidazol-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-dimethyl-amine;
 dimethyl-{6-[4-(1H-pyrrol-2-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
 [6-(4-Butoxymethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-dimethyl-amine;
 dimethyl-[6-(4-tetrazol-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine;
 3-[4-(4-Dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzylamino]-propan-1-ol;
 [6-(4-[(2-Methoxy-ethyl)-methyl-amino]-methyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-dimethyl-amine;
 3-{4-[4-(3-Morpholin-4-yl-propylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-pentan-3-ol;
 2-{4-[4-[Bis-(2-methoxy-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-propan-2-ol;
 3-{4-[4-[Bis-(2-methoxy-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-pentan-3-ol;
 3-{4-[4-(3-Pyrrol-1-yl-propylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-pentan-3-ol;
 2-[4-(4-Dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-propan-2-ol;
 2-[4-(4-Methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-propan-2-ol;
 or a pharmaceutically acceptable salt thereof.

6. (Original) A compound of formula I according to claim 1 selected from the group consisting of
 [4-(4-methylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-morpholin-4-yl-methanone;
 [4-(4-dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-morpholin-4-yl-methanone;
 {4-[4-(ethyl-methyl-amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone;
 isopropyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
 ethyl-methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
 methyl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
 [6-(4-Imidazol-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-dimethyl-amine;
 2-[4-(4-Dimethylamino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-propan-2-ol;
 or a pharmaceutically acceptable salt thereof.

7. (Currently Amended) A compound of formula I, or a pharmaceutically acceptable salt thereof, according to ~~any one of claims 1~~ for use in a method for the treatment of the human or animal body.

8. (Currently Amended) A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1~~ together with at least one pharmaceutically acceptable carrier.

9. (Currently Amended) aA compound of formula I according to ~~any one of~~ claims 1 or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.

10.-13. (Cancelled)

14. (Withdrawn) All novel compounds, methods, processes and uses substantially as hereinbefore described with particular reference to the examples.